Fig. 2 | Eye

Fig. 2

From: Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis

Fig. 2

a Pathogenic autoantibodies stimulating the orbital fibroblasts resulting in production of hyaluronan and giving rise to symptoms of thyroid eye disease. b Teprotumumab (an IGF-1R antagonist) blocks the stimulatory effects of pathogenic autoantibodies on the orbital fibroblasts TSI thyroid stimulating immunoglobulins, GD-IgG Graves’ disease immunoglobulins, TSHR thyroid stimulating hormone receptor, IGF-1R insulin-like growth factor-1 receptor

Back to article page